Chi et al., 2010 - Google Patents
ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumoursChi et al., 2010
View PDF- Document ID
- 1603384388660841096
- Author
- Chi P
- Chen Y
- Zhang L
- Guo X
- Wongvipat J
- Shamu T
- Fletcher J
- Dewell S
- Maki R
- Zheng D
- Antonescu C
- Allis C
- Sawyers C
- Publication year
- Publication venue
- Nature
External Links
Snippet
Gastrointestinal stromal tumour (GIST) is the most common human sarcoma and is primarily defined by activating mutations in the KIT or PDGFRA receptor tyrosine kinases,. KIT is highly expressed in interstitial cells of Cajal (ICCs)—the presumed cell of origin for GIST—as …
- 101700001792 ETV1 0 title abstract description 180
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chi et al. | ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours | |
| Xue et al. | SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer | |
| Picco et al. | Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screening | |
| Jin et al. | Targeting glioma stem cells through combined BMI1 and EZH2 inhibition | |
| Harlander et al. | Combined mutation in Vhl, Trp53 and Rb1 causes clear cell renal cell carcinoma in mice | |
| Strub et al. | SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling | |
| Giltnane et al. | Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance | |
| Abraham et al. | Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells | |
| Lu et al. | lncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/β-catenin signaling | |
| Kourtis et al. | Oncogenic hijacking of the stress response machinery in T cell acute lymphoblastic leukemia | |
| Knoechel et al. | An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia | |
| Arriaga et al. | A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance | |
| Carter et al. | Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma | |
| Liu et al. | HOTAIR, a long noncoding RNA, is a marker of abnormal cell cycle regulation in lung cancer | |
| Balko et al. | Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance | |
| Zuber et al. | RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia | |
| Vizoso et al. | Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR | |
| Lin et al. | Genomic and molecular characterization of esophageal squamous cell carcinoma | |
| Rathert et al. | Transcriptional plasticity promotes primary and acquired resistance to BET inhibition | |
| Fillmore et al. | EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors | |
| Chen et al. | MicroRNA-211 enhances the oncogenicity of carcinogen-induced oral carcinoma by repressing TCF12 and increasing antioxidant activity | |
| Liu et al. | Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers | |
| Shy et al. | Regulation of Tcf7l1 DNA binding and protein stability as principal mechanisms of Wnt/β-catenin signaling | |
| Guo et al. | Androgen receptor and MYC equilibration centralizes on developmental super-enhancer | |
| Bi et al. | Decreased ZNF750 promotes angiogenesis in a paracrine manner via activating DANCR/miR-4707-3p/FOXC2 axis in esophageal squamous cell carcinoma |